Hypercalcemic Patient Diagnosed With Primary Hyperparathyroidism After Dapagliflozin Treatment
Open Access
- 1 November 2020
- journal article
- Published by Elsevier BV in AACE Clinical Case Reports
- Vol. 6 (6), e319-e321
- https://doi.org/10.4158/accr-2020-0113
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Mineral and Electrolyte Disorders With SGLT2i TherapyJBMR Plus, 2019
- Effects of Dapagliflozin on Circulating Markers of Phosphate HomeostasisClinical Journal of the American Society of Nephrology, 2018
- Hipercalcemia inducida por dapagliflozinaNefrología, 2018
- Canagliflozin triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover studyJCI Insight, 2018
- SGLT2 inhibitors-induced electrolyte abnormalities: An analysis of the associated mechanismsDiabetes & Metabolic Syndrome: Clinical Research & Reviews, 2018
- Renal, metabolic and cardiovascular considerations of SGLT2 inhibitionNature Reviews Nephrology, 2016
- Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trialsDiabetologia, 2016